iifl-logo-icon 1

Caplin Point Laboratories Ltd Share Price

1,748.75
(-1.44%)
Aug 23, 2024|03:32:37 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,778
  • Day's High1,778
  • 52 Wk High1,900
  • Prev. Close1,774.3
  • Day's Low1,742
  • 52 Wk Low954
  • Turnover (lac)1,477.08
  • P/E48.23
  • Face Value2
  • Book Value196.84
  • EPS36.83
  • Mkt. Cap (Cr.)13,292.55
  • Div. Yield0.14
View All Historical Data
No Records Found

Caplin Point Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,778

Prev. Close

1,774.3

Turnover(Lac.)

1,477.08

Day's High

1,778

Day's Low

1,742

52 Week's High

1,900

52 Week's Low

954

Book Value

196.84

Face Value

2

Mkt Cap (₹ Cr.)

13,292.55

P/E

48.23

EPS

36.83

Divi. Yield

0.14

Caplin Point Laboratories Ltd Corporate Action

16 May 2024

12:00 AM

Dividend

Dividend Amount: 2.5

Record Date: 31 May, 2024

arrow

8 Aug 2023

12:00 AM

BookCloser

arrow

7 Aug 2023

12:00 AM

AGM

Announcement Date: 07 Aug, 2023

arrow

31 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Caplin Point Laboratories Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Caplin Point Laboratories Ltd SHAREHOLDING SNAPSHOT

24 Aug, 2024|08:37 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 70.56%

Foreign: 0.00%

Indian: 70.56%

Non-Promoter- 4.86%

Institutions: 4.86%

Non-Institutions: 24.57%

Custodian: 0.00%

Share Price

Caplin Point Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

15.18

15.16

15.13

15.13

Preference Capital

0

0

0

0

Reserves

1,124.73

915.49

743.54

584.78

Net Worth

1,139.91

930.65

758.67

599.91

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

482.67

527.82

426.57

341.54

yoy growth (%)

-8.55

23.73

24.89

47.67

Raw materials

-194.83

-238.17

-180.11

-161.93

As % of sales

40.36

45.12

42.22

47.41

Employee costs

-26.59

-24.99

-38.82

-30.58

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

209.93

253.12

146.05

92.57

Depreciation

-22.44

-19.65

-18.98

-13.25

Tax paid

-53.71

-55.48

-43.74

-22.26

Working capital

168.2

177.62

44.02

40.41

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

-8.55

23.73

24.89

47.67

Op profit growth

3.34

45.98

51.72

49.97

EBIT growth

-17.05

73.36

57.61

58.5

Net profit growth

-20.95

93.17

45.49

55.13

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,694.1

1,466.73

1,269.41

1,061.29

863.2

Excise Duty

0

0

0

0

0

Net Sales

1,694.1

1,466.73

1,269.41

1,061.29

863.2

Other Operating Income

0

0

0

0

0

Other Income

67.21

56.06

38.75

23.54

41.33

Caplin Point Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,775.75

150.914,20,027.58237.820.774,409.7498.75

Divis Laboratories Ltd

DIVISLAB

4,855.95

78.491,30,370.294300.612,063507.93

Cipla Ltd

CIPLA

1,574.55

32.241,28,058.811,055.940.823,752.25346.4

Zydus Lifesciences Ltd

ZYDUSLIFE

1,178.7

27.871,21,729.161,700.80.254,035.4156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,954.5

28.241,16,346.951,417.20.575,823.91,458.7

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Caplin Point Laboratories Ltd

Management

Register Office

Registrar Office

Chairman & Non Executive Dir.

C C Paarthipan

Independent Non Exe. Director

D Sathyanarayanan

Independent Director

C K Gariyali

Independent Non Exe. Director

Deenadayalan Singaram

Independent Non Exe. Director

R Nagendran

Managing Director

Sridhar Ganesan

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections.Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil).The company came out with a public issue in Nov.94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord L
Read More

Company FAQs

What is the Caplin Point Laboratories Ltd share price today?

Down Arrow

The Caplin Point Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1748.75 today.

What is the Market Cap of Caplin Point Laboratories Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Caplin Point Laboratories Ltd is ₹13292.55 Cr. as of 23 Aug ‘24

What is the PE and PB ratio of Caplin Point Laboratories Ltd?

Down Arrow

The PE and PB ratios of Caplin Point Laboratories Ltd is 48.23 and 9.71 as of 23 Aug ‘24

What is the 52 Week High and Low of Caplin Point Laboratories Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Caplin Point Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Caplin Point Laboratories Ltd is ₹954 and ₹1900 as of 23 Aug ‘24

What is the CAGR of Caplin Point Laboratories Ltd?

Down Arrow

Caplin Point Laboratories Ltd's CAGR for 5 Years at 34.47%, 3 Years at 36.09%, 1 Year at 72.37%, 6 Month at 16.62%, 3 Month at 37.20% and 1 Month at 20.10%.

What is the shareholding pattern of Caplin Point Laboratories Ltd?

Down Arrow

The shareholding pattern of Caplin Point Laboratories Ltd is as follows:
Promoters - 70.56 %
Institutions - 4.87 %
Public - 24.57 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp